3,452 results on '"liver stiffness"'
Search Results
2. Redox Homeostasis and Non-Invasive Assessment of Significant Liver Fibrosis by Shear Wave Elastography.
- Author
-
Egresi, Anna, Blázovics, Anna, Lengyel, Gabriella, Tóth, Adrienn Gréta, Csongrády, Barbara, Jakab, Zsuzsanna, and Hagymási, Krisztina
- Subjects
- *
HEPATIC fibrosis , *LIVER disease etiology , *SHEAR waves , *OXIDATIVE stress , *SULFHYDRYL group - Abstract
Hepatic fibrosis with various origins can be estimated non-invasively by using certain biomarkers and imaging-based measurements. The aim of our study was to examine redox homeostasis biomarkers and liver stiffness measurements for the assessment of significant liver fibrosis in different etiologies of chronic liver diseases. A cohort study consisting of 88 chronic liver disease patients of both sexes (age 49.1 ± 14.7 years) was performed. Cytokine profiles as well as redox homeostasis characteristics were determined. Liver fibrosis stages were assessed with shear wave elastography. The plasma levels of four cytokines showed no significant alteration between the four fibrotic stages; however, higher values were measured in the F2–4 stages. Free sulfhydryl group concentration, the marker of redox homeostasis, was lower in significant fibrosis (F0–F1: 0.36 ± 0.06 vs. F2–4: 0.29 ± 0.08 mmol/L, p < 0.05). Higher chemiluminescence values, as free radical–antioxidant parameters, were detected in advanced fibrosis stages in erythrocytes (F0–F1: 36.00 ± 37.13 vs. F2–4: 51.47 ± 44.34 RLU%). These data suggest that oxidative stress markers can predict significant fibrosis, with the aim of reducing the number of protocol liver biopsies in patients unlikely to have significant disease; however, their role in distinguishing between the certain fibrosis groups needs further studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study.
- Author
-
Kumada, Takashi, Toyoda, Hidenori, Ogawa, Sadanobu, Gotoh, Tatsuya, Yoshida, Yuichi, Yamahira, Masahiro, Hirooka, Masashi, Koizumi, Yohei, Hiasa, Yoichi, Tamai, Tsutomu, Kuromatsu, Ryoko, Matsuzaki, Toshihisa, Suehiro, Tomoyuki, Kamada, Yoshihiro, Sumida, Yoshio, Tanaka, Junko, and Shimizu, Masahito
- Subjects
- *
RECEIVER operating characteristic curves , *HEPATIC fibrosis , *BODY mass index , *SHEAR waves , *MAGNETIC resonance - Abstract
Aim: This study aimed to establish the shear wave measurement (SWM) cut‐off value for each fibrosis stage using magnetic resonance (MR) elastography values as a reference standard. Methods: We prospectively analyzed 594 patients with chronic liver disease who underwent SWM and MR elastography. Correlation coefficients (were analyzed, and the diagnostic value was evaluated by the area under the receiver operating characteristic curve. Liver stiffness was categorized by MR elastography as F0 (<2.61 kPa), F1 (≥2.61 kPa, <2.97 kPa, any fibrosis), F2 (≥2.97 kPa, <3.62 kPa, significant fibrosis), F3 (≥3.62 kPa, <4.62 kPa, advanced fibrosis), or F4 (≥4.62 kPa, cirrhosis). Results: The median SWM values increased significantly with increasing fibrosis stage (p < 0.001). The correlation coefficient between SWM and MR elastography values was 0.793 (95% confidence interval 0.761–0.821). The correlation coefficients between SWM and MR elastography values significantly decreased with increasing body mass index and skin–capsular distance; skin–capsular distance values were associated with significant differences in sensitivity, specificity, accuracy, or positive predictive value, whereas body mass index values were not. The best cut‐off values for any fibrosis, significant fibrosis, advanced fibrosis, and cirrhosis were 6.18, 7.09, 8.05, and 10.89 kPa, respectively. Conclusions: This multicenter study in a large number of patients established SWM cut‐off values for different degrees of fibrosis in chronic liver diseases using MR elastography as a reference standard. It is expected that these cut‐off values will be applied to liver diseases in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes.
- Author
-
Al‐Ozairi, Ebaa, Irshad, Mohammad, AlKandari, Jumana, Mashankar, Anant, Alroudhan, Dherar, and le Roux, Carel W.
- Subjects
- *
TYPE 1 diabetes , *HEPATIC fibrosis , *TYPE 2 diabetes , *MAGNETIC resonance imaging , *GLYCEMIC control - Abstract
Aim: To compare hepatic stiffness and fat fraction in patients with obesity and type 1 diabetes (T1D) with type 2 diabetes (T2D) with a similar body mass index (BMI). Methods: In this prospective cross‐sectional study, 90 participants with T1D (BMI 30.5 ± 4.5 kg/m2; diabetes duration 20.5 ± 9.8 years; HbA1c 8.2% ± 1.4%) and 69 with T2D (BMI: 30.8 ± 4.6 kg/m2; diabetes duration: 11.7 ± 7.8 years; HbA1c: 7.3% ± 1.4%) were included. Liver fat fraction and stiffness were examined by magnetic resonance imaging and elastography, respectively. Logistic regressions were used to evaluate associations with biomedical variables. Results: The mean liver stiffness score in patients with obesity and T1D was 2.2 ± 0.5 kPa, while in T2D it was 2.6 ± 0.8 kPa (P <.001). The liver fat fraction in patients with obesity and T1D was 3.7% ± 6.3%, and in T2D it was 10.6% ± 7.9% (P <.001). Metabolic dysfunction‐associated steatotic liver disease (MASLD) was present in 13.3% of patients with T1D and in 69.6% of patients with T2D, whereas fibrosis was suggested in 7.8% of patients with T1D and in 27.5% of patients with T2D. Liver stiffness was four times higher in patients with T2D compared with those with T1D (odds ratio = 5.4, 95% confidence interval: 2.1‐13.6, P <.001). Aspartate transaminase (AST), alanine transaminase, gamma‐glutamyl transferase (GGT), triglycerides and the android‐to‐gynoid ratio were associated with elevated fat fraction in both cohorts. AST and GGT were associated with elevated liver stiffness in both cohorts. Conclusions: Patients with obesity and T1D had lower liver fat and liver stiffness compared with those patients with T2D, despite similar levels of BMI, a longer duration of diabetes and worse glycaemic control. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Magnetic resonance elastography (MRE) outperforms acoustic force radiation impulse (ARFI) in predicting oesophageal varices in obese NAFLD cirrhosis.
- Author
-
Roy, Akash, Verma, Nipun, Jajodia, Surabhi, Goenka, Usha, Tiwari, Awanish, Sonthalia, Nikhil, and Goenka, Mahesh
- Subjects
- *
NON-alcoholic fatty liver disease , *ESOPHAGEAL varices , *RECEIVER operating characteristic curves , *INDEPENDENT variables , *ACOUSTIC radiation - Abstract
Purpose: Liver stiffness measurement (LSM) by transient elastography has been shown to underperform in high-risk varices (HRVs) prediction in obese non-alcoholic fatty liver disease (NAFLD) compensated cirrhosis (CC). LSM by magnetic resonance elastography (MRE) and acoustic force radiation impulse (ARFI) has been shown to be useful in prediction of oesophageal varices (EVs), but has limited evidence in obese NAFLD-CC. Methods: Obese patients with NAFLD-CC who underwent MRE and ARFI for LSM and endoscopy for screening of varices were enrolled. Performance of MRE and ARFI for predicting EVs or HRVs was evaluated using area under receiver operating characteristics (AUROC) curves and regression analyses were performed for predictor variables. Results: One hundred eight patients [mean age 54.7 ± 9.6 years, median BMI, 28.5 (26.4–30.0) kg/m2. 72.2% diabetics, 45.4% hypertensive] were enrolled. Fifty-two (48.1%) had no varices, while 29 (26.8%) and 27 (25%) had low-risk varices (LRVs) and HRVs, respectively. MRE-LSM was higher in patients with LRVs (p = 0.01) or HRVs (p = 0.001) against those without varices. ARFI-LSM did not differ significantly between those without and with LRVs or HRVs (p > 0.05 for all). There was a low correlation between ARFI-LSM and MRE-LSM in the overall cohort (r = 0.19). Only platelet count (PC) [0.98 (0.97–0.99)] and MRE-LSM [1.8 (1.26–2.79)] were predictors of HRVs. At a cut-off of 4.75, MRE showed a sensitivity of 96.3%. Model combining MRE-LSM with PC had a diagnostic AUROC of 0.77 and 0.76 for EVs and HRVs. Conclusion: In obese NAFLD-CC, MRE-LSM is significantly higher in patients with varices. MRE combined with PC predicts EVs and HRVs with better accuracy than ARFI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Associations Between Multiparametric US-Based Indicators and Pathological Status in Patients with Metabolic Associated Fatty Liver Disease.
- Author
-
Zhou, Yan, Nie, Mengjin, Mao, Feng, Zhou, Hongyu, Zhao, Lin, Ding, Jianmin, Kan, Yanmin, and Jing, Xiang
- Subjects
- *
FATTY liver , *RECEIVER operating characteristic curves , *ATTENUATION coefficients , *SHEAR waves , *LIVER biopsy - Abstract
Noninvasive evaluation of metabolic dysfunction-associated fatty liver disease (MAFLD) using ultrasonography holds significant clinical value. The associations between ultrasound (US)-based parameters and the pathological spectra remain unclear and controversial. This study aims to investigate the associations thoroughly. The participants with MAFLD undergoing liver biopsy and multiparametric ultrasonography were prospectively recruited from December 2020 to September 2022. Three US-based parameters, namely attenuation coefficient (AC), liver stiffness (LS) and dispersion slope (DS) were obtained. The relationship between these parameters and steatosis grades, inflammation grades and fibrosis stages was examined. In this study with 116 participants, AC values significantly differed across distinct steatosis grades (p < 0.001), while DS and LS values varied among inflammation grades (p < 0.001) and fibrosis stages (p < 0.001). The area under the receiver operating characteristic curves (AUCs) of AC ranged from 0.82 to 0.84 for differentiating steatosis grades, while AUCs of LS ranged from 0.62 to 0.76 for distinguishing inflammation grades and 0.83–0.95 for discerning fibrosis stages. AUCs for DS ranged from 0.79 to 0.81 in discriminating inflammation grades and 0.80–0.88 for differentiating fibrosis stages. Subgroup analysis revealed that LS demonstrated different trends in inflammation grade but consistent trends in fibrosis stage across subgroups, whereas DS showed consistent trends for both inflammation grade and fibrosis stage across all subgroups. AC values indicate the degree of hepatic steatosis but not inflammation or fibrosis. LS values are determined only by fibrosis stage and are not associated with inflammation grades. DS values are associated with both fibrosis and inflammation grades. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Prognostic value of liver stiffness in patients hospitalized for acute decompensated heart failure: a meta-analysis.
- Author
-
Macerola, Noemi, Riccardi, Laura, Di Stasio, Enrico, Montalto, Massimo, Gasbarrini, Antonio, Pompili, Maurizio, and Garcovich, Matteo
- Abstract
Purpose: Heart failure (HF) is a major health problem affecting millions of people worldwide. In the latest years, many efforts have been made to identify predictors of poor prognosis in these patients. The aim of this systematic review and meta-analysis was to enlighten the correlation between liver stiffness (LS), assessed by Shear Wave Elastography techniques, and HF, particularly focusing on the prognostic value of LS on cardiovascular outcomes. Methods: We searched the PUBMED databases (up to May 1st, 2023) for studies that enlightened the correlation between LS and cardiovascular outcomes in patients hospitalized for acute decompensated heart failure (ADHF). We performed a meta-analysis to estimate the efficacy of LS in predicting the prognosis of patients with ADHF. Results: We analyzed data from 7 studies, comprising 677 patients, that assessed the prognostic value of LS in predicting cardiovascular outcomes in patients hospitalized for ADHF. The pooled analysis showed that increased liver stiffness was associated with higher risk of adverse cardiac events (hazard ratio 1.07 [1.03, 1.12], 95% CI). Conclusion: Increased LS is associated with poor prognosis in patients hospitalized for HF and might help effectively identify those patients at high risk for worse outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.
- Author
-
Jin, Yufeng, Wang, Xin, Chen, Ke, Chen, Yu, Zhou, Lixin, Zeng, Yupeng, Zhou, Yuqing, Pan, Zhijun, Wang, Di, Li, Zhongxia, Liang, Yongqian, Ling, Wenhua, and Li, Dan
- Subjects
- *
GUT microbiome , *SILYMARIN , *FATTY liver , *RANDOMIZED controlled trials , *SPECIES diversity , *GAMMA-glutamyltransferase - Abstract
Background: Despite centuries of traditional use of silymarin for hepatoprotection, current randomized controlled trial (RCT) studies on the effectiveness of silymarin in managing metabolic dysfunction-associated steatotic liver disease (MASLD) are limited and inconclusive, particularly when it is administered alone. The low bioavailability of silymarin highlights the possible influence of gut microbiota on the effectiveness of silymarin; however, no human studies have investigated this aspect. Objective: To determine the potential efficacy of silymarin in improving MASLD indicators and to investigate the underlying mechanisms related to gut microbiota. Method: In this 24-week randomized, double-blind, placebo-controlled trial, 83 patients with MASLD were randomized to either placebo (n = 41) or silymarin (103.2 mg/d, n = 42). At 0, 12, and 24 weeks, liver stiffness and hepatic steatosis were assessed using FibroScan, and blood samples were gathered for biochemical detection, while faecal samples were collected at 0 and 24 weeks for 16S rRNA sequencing. Results: Silymarin supplementation significantly reduced liver stiffness (LSM, -0.21 ± 0.17 vs. 0.41 ± 0.17, P = 0.015) and serum levels of γ-glutamyl transpeptidase (GGT, -8.21 ± 3.01 vs. 1.23 ± 3.16, P = 0.042) and ApoB (-0.02 ± 0.03 vs. 0.07 ± 0.03, P = 0.023) but had no significant effect on the controlled attenuation parameter (CAP), other biochemical indicators (aminotransferases, total bilirubin, glucose and lipid parameters, hsCRP, SOD, and UA), physical measurements (DBP, SBP, BMI, WHR, BF%, and BMR), or APRI and FIB-4 indices. Gut microbiota analysis revealed increased species diversity and enrichment of Oscillospiraceae in the silymarin group. Conclusion: These findings suggest that silymarin supplementation could improve liver stiffness in MASLD patients, possibly by modulating the gut microbiota. Trial registration: The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2200059043). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Reference values and associated factors of controlled attenuation parameter and liver stiffness in adults: A cross-sectional study.
- Author
-
Ramírez-Vélez, Robinson, Izquierdo, Mikel, García-Hermoso, Antonio, and Correa-Rodríguez, María
- Abstract
The utilization of non-invasive techniques for liver fibrosis and steatosis assessment has gained acceptance as a viable substitute for liver biopsy in clinical practice. This study aimed to establish normative data for the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) by age and gender, as well as to explore the relationship between anthropometric measures, clinical status, and biochemical profile according to the 90th percentile cut-off values for CAP/LSM in a U.S. adult population. In this cross-sectional analysis, 7.522 US adults aged 20–80 years from the National Health and Nutrition Examination Survey (NHANES 2017–2020) were included. CAP and LSM were quantified using the FibroScan® 502-v2 device. A comprehensive range of data was collected, including sociodemographic, anthropometric, biochemical, lifestyle, and clinical conditions. Participants were segmented by sex and age. The median ± standard deviation (SD) for CAP was significantly lower in women (258.27 ± 61.02 dB/m) than in men (273.43 ± 63.56 dB/m), as was the median ± SD for LSM (women: 5.50 ± 4.12 kPa, men: 6.36 ± 5.63 kPa). Although median CAP and LSM values displayed an upward trend with age, statistical significance was not achieved. Notably, higher liver CAP values (above the 90th percentile) correlated with more pronounced clinical and biochemical profile differences compared to lower CAP values (below the 90th percentile) (p < 0.001). Our study provides age- and sex-stratified standard values for CAP and LSM in a sizeable, nationally representative cohort of adults. The evidence of sex-specific variations in TE test results from our study sets the stage for future research to further corroborate these findings. • Transient Elastography (TE) with controlled attenuation parameter (CAP) and liver stiffness measurement (LMS) are non-invasive techniques for quantifying liver fat. • Normative references for CAP and LSM may enhance the detection of at-risk individuals for liver steatosis through population-wide TE-based preventative programs. • CAP and LSM metrics were notably higher in men than in women. • Higher CAP values correspond with substantial differences in clinical and biochemical profiles. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Jiangzhi Paizhuo Decoction Combined with Silibinin Capsules Improve the Outcomes of Metabolic Associated Fatty Liver Disease.
- Author
-
Jianmei Hao, Yuanjing Xie, Zhiping Yang, Jianwei Dou, Minghua Mao, and Xiaofang Li
- Subjects
FATTY liver ,ORAL drug administration ,CHINESE medicine ,SILIBININ ,MENTAL depression - Abstract
The study aimed to evaluate the impact of combining silibinin capsules with Jiangzhi Paizhuo Decoction (JZPZ) versus silibinin capsules alone in patients with MAFLD. The research was carried out at the Xi'an Hospital of Traditional Chinese Medicine using a case-control design following to STROBE guideline. Eligible participants meeting the inclusion criteria were randomly allocated into two groups. The participants in control group and intervention group were assigned to receive oral administration of 70 mg (3 times daily) silibinin capsules or 70 mg silibinin capsules (3 times daily) plus colon dialysis with 150 ml JZPZ decoction for 8 weeks. The primary outcome and secondary outcome on the effects of JZPZ decoction in MAFLD were detected. We found that liver function significantly improved in both groups after treatment (p < 0.05) compared with the baseline. Importantly, JZPZ decoction was associated with significant decrease in hepatic steatosis (CAP changes: −18.91 ± 11.50 vs −26.86 ± 16.62, P = 0.0305). The JZPZ decoction reduced significantly the TCM syndromes score compared to control (−5.74 ± 0.95 versus −7.17 ± 1.23, P < 0.0001). Meanwhile, the weight and BMI in JZPZ group increased significantly more than control group (P = 0.0003, P < 0.0001). In conclusion, the JZPZ decoction combined with silibinin capsules in the treatment of MAFLD patients with liver depression and heat syndrome has more advantages in decreasing hepatic steatosis and TCM syndromes scores. It is worthy of clinical recommendation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine.
- Author
-
Suffredini, Giancarlo, Gao, Wei Dong, and Dodd-o, Jeffrey M.
- Subjects
- *
SHEAR waves , *TECHNOLOGICAL risk assessment , *HEPATIC fibrosis , *ELASTOGRAPHY , *ULTRASONIC imaging - Abstract
Ultrasound shear wave elastography (SWE) is a non-invasive, low risk technology allowing the assessment of tissue stiffness. Used clinically for nearly two decades to diagnose and stage liver fibrosis and cirrhosis, it has recently been appreciated for its ability to differentiate between more subtle forms of liver dysfunction. In this review, we will discuss the principle of ultrasound shear wave elastography, its traditional utilization in grading liver cirrhosis, as well as its evolving role in identifying more subtle degrees of liver injury. Finally, we will show how this capacity to distinguish nuanced changes may provide an opportunity for its use in perioperative risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease.
- Author
-
Nakano, Masahito, Kawaguchi, Machiko, Kawaguchi, Takumi, and Yoshiji, Hitoshi
- Subjects
- *
HEPATIC fibrosis , *ALANINE aminotransferase , *LIVER diseases , *METABOLIC disorders , *SHEAR waves - Abstract
Aim: In patients with steatotic liver disease (SLD), significant hepatic fibrosis is a prognostic factor with various etiologies, including inflammation and metabolic dysfunction. This study aimed to investigate independent factors and profiles associated with significant hepatic fibrosis, including alanine aminotransferase (ALT) levels >30 U/L and metabolic dysfunction‐associated SLD (MASLD), in health check‐up examinees. Methods: This single‐center, retrospective, observational cohort study enrolled 1378 consecutive health checkup examinees from April 2018 to September 2022. Shear wave elastography (SWE) was performed during a routine ultrasound examination, and patients with liver stiffness ≥6.60 kPa were defined as having significant hepatic fibrosis. Patients were classified into nonsignificant hepatic fibrosis (n = 1220) or a significant hepatic fibrosis (n = 158) group according to this definition. Results: In multivariate analysis, the independent factor for significant hepatic fibrosis was aging (≥65 years; OR 9.637, 95% CI 6.704–13.852, p < 0.0001). According to decision tree analysis, the initial classifier was aging (≥65 years). After aging, an ALT level >30 U/L was the second relevant factor for significant hepatic fibrosis, regardless of age. An undirected graphical model showed that an ALT level of >30 U/L was directly associated with significant hepatic fibrosis. In patients aged ≥65 years with an ALT level >30 U/L, significant hepatic fibrosis was observed in 52% of the patients. Meanwhile, in patients aged ≥65 years with an ALT level ≤30 U/L, MASLD was the third classifier, with significant hepatic fibrosis observed in 38% of patients. Conclusions: ALT levels >30 U/L and MASLD may be involved in the pathogenesis of significant hepatic fibrosis in patients aged ≥65 years. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review.
- Author
-
Amoroso, Mattia, Augustin, Salvador, Moosmang, Sven, and Gashaw, Isabella
- Subjects
- *
PROGNOSIS , *HEPATIC fibrosis , *NEUTROPHIL lymphocyte ratio , *CIRRHOSIS of the liver , *NON-alcoholic fatty liver disease , *JOINT stiffness - Abstract
Liver cirrhosis due to nonalcoholic steatohepatitis (NASH) is a life-threatening condition with increasing incidence world-wide. Although its symptoms are unspecific, it can lead to decompensation events such as ascites, hepatic encephalopathy, variceal hemorrhage, and hepatocellular carcinoma (HCC). In addition, an increased risk for cardiovascular events has been demonstrated in patients with NASH. Pharmacological treatments for NASH cirrhosis are not yet available, one of the reasons being the lack in surrogate endpoints available in clinical trials of NASH cirrhosis. The feasibility of non-invasive prognostic biomarkers makes them interesting candidates as possible surrogate endpoints if their change following treatment would result in better outcomes for patients in future clinical trials of NASH cirrhosis. In this systematic literature review, a summary of the available literature on the prognostic performance of non-invasive biomarkers in terms of cardiovascular events, liver-related events, and mortality is outlined. Due to the scarcity of data specific for NASH cirrhosis, this review includes studies on NAFLD whose evaluation focuses on cirrhosis. Our search strategy identified the following non-invasive biomarkers with prognostic value in studies of NASH patients: NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4), aspartate aminotransferase (AST) to platelet ratio index (APRI), enhanced liver fibrosis (ELF™), BARD (BMI, AST/ALT (alanine aminotransferase) ratio, diabetes), Hepamet Fibrosis Score (HFS), liver enzymes (AST + ALT), alpha-fetoprotein, platelet count, neutrophil to lymphocyte ratio (NLR), Lysyl oxidase-like (LOXL) 2, miR-122, liver stiffness, MEFIB (liver stiffness measured with magnetic resonance elastography (MRE) + FIB-4), and PNPLA3 GG genotype. The aim of the present systematic literature review is to provide the reader with a summary of the non-invasive biomarkers with prognostic value in NASH cirrhosis and give an evaluation of their utility as treatment monitoring biomarkers in future clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Liver stiffness measurement by magnetic resonance elastography predicts cirrhosis and decompensation in alcohol-related liver disease.
- Author
-
Chen, Jingbiao, Xu, Peng, Kalutkiewicz, Kyle, Sheng, Yiyang, Warsame, Fatima, Tahboub-Amawi, Mahmoud-Adam, Li, Jiahui, Wang, Jin, Venkatesh, Sudhakar K., Ehman, Richard L., Shah, Vijay H., Simonetto, Douglas A., and Yin, Meng
- Subjects
- *
TEMPERANCE , *ELECTRONIC health records , *MAGNETIC measurements , *ALCOHOL-induced disorders , *LIVER diseases - Abstract
Purpose: To evaluate magnetic resonance elastography (MRE)—based liver stiffness measurement as a biomarker to predict the onset of cirrhosis in early-stage alcohol-related liver disease (ALD) patients, and the transition from compensated to decompensated cirrhosis in ALD. Methods: Patients with ALD and at least one MRE examination between 2007 and 2020 were included in this study. Patient demographics, liver chemistries, MELD score (within 30 days of the first MRE), and alcohol abstinence history were collected from the electronic medical records. Liver stiffness and fat fraction were measured. Disease progression was assessed in the records by noting cirrhosis onset in early-stage ALD patients and decompensation in those initially presenting with compensated cirrhosis. Nomograms and cut-off values of liver stiffness, derived from Cox proportional hazards models were created to predict the likelihood of advancing to cirrhosis or decompensation. Results: A total of 182 patients (132 men, median age 57 years) were included in this study. Among 110 patients with early-stage ALD, 23 (20.9%) developed cirrhosis after a median follow-up of 6.2 years. Among 72 patients with compensated cirrhosis, 33 (45.8%) developed decompensation after a median follow-up of 4.2 years. MRE-based liver stiffness, whether considered independently or adjusted for age, alcohol abstinence, fat fraction, and sex, was a significant and independent predictor for both future cirrhosis (Hazard ratio [HR] = 2.0–2.2, p = 0.002–0.003) and hepatic decompensation (HR = 1.2–1.3, p = 0.0001–0.006). Simplified Cox models, thresholds, and corresponding nomograms were devised for practical use, excluding non-significant or biased variables. Conclusions: MRE-based liver stiffness assessment is a useful predictor for the development of cirrhosis or decompensation in patients with ALD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Liver Stiffness Evaluation in Chronic Hepatitis C Patients with Cirrhosis before and after Direct-Acting Antivirals.
- Author
-
Stasi, Cristina and Brillanti, Stefano
- Subjects
CHRONIC hepatitis C ,HEPATIC fibrosis ,HEPATITIS C virus ,PROGNOSIS ,CIRRHOSIS of the liver - Abstract
After the introduction of direct-acting antivirals, parallel significant clinical progress has been achieved in the assessment of liver fibrosis progression/regression before treatment and during the follow-up of the cirrhotic patients with chronic hepatitis C virus (HCV) infection. The evolution of chronic hepatitis C into liver cirrhosis is correlated with an extensive accumulation of the extracellular matrix, leading to the formation of large amounts of fibrotic tissues that, initially, are concentrated in periportal areas and, in the later stages, surround the nodules of regenerating hepatocytes. The progressive increase in the fibrotic matrix contributes to vascular disturbances (favoring the development of portal hypertension) and to microenvironmental changes. The four clinical stages of liver cirrhosis are predictors for different clinical scenarios. The wide-ranging functions of the liver require different methods for their assessment. The non-invasive evaluation using transient elastography is useful in determining the longitudinal modifications of fibrosis during and after treatment with direct-acting antivirals. The liver stiffness evaluation, known to have a wide range of values in cirrhotic patients, can offer different prognostic implications after sustained virological response. This review discusses the different time points of liver stiffness evaluation that appear to show a more well-defined propensity to identify adequate monitoring schedules for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial
- Author
-
Yufeng Jin, Xin Wang, Ke Chen, Yu Chen, Lixin Zhou, Yupeng Zeng, Yuqing Zhou, Zhijun Pan, Di Wang, Zhongxia Li, Yongqian Liang, Wenhua Ling, and Dan Li
- Subjects
Metabolic dysfunction-associated steatotic liver disease ,Silymarin ,Liver stiffness ,Gut microbiota ,Randomized controlled study ,Flavonoids ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Despite centuries of traditional use of silymarin for hepatoprotection, current randomized controlled trial (RCT) studies on the effectiveness of silymarin in managing metabolic dysfunction-associated steatotic liver disease (MASLD) are limited and inconclusive, particularly when it is administered alone. The low bioavailability of silymarin highlights the possible influence of gut microbiota on the effectiveness of silymarin; however, no human studies have investigated this aspect. Objective To determine the potential efficacy of silymarin in improving MASLD indicators and to investigate the underlying mechanisms related to gut microbiota. Method In this 24-week randomized, double-blind, placebo-controlled trial, 83 patients with MASLD were randomized to either placebo (n = 41) or silymarin (103.2 mg/d, n = 42). At 0, 12, and 24 weeks, liver stiffness and hepatic steatosis were assessed using FibroScan, and blood samples were gathered for biochemical detection, while faecal samples were collected at 0 and 24 weeks for 16S rRNA sequencing. Results Silymarin supplementation significantly reduced liver stiffness (LSM, -0.21 ± 0.17 vs. 0.41 ± 0.17, P = 0.015) and serum levels of γ-glutamyl transpeptidase (GGT, -8.21 ± 3.01 vs. 1.23 ± 3.16, P = 0.042) and ApoB (-0.02 ± 0.03 vs. 0.07 ± 0.03, P = 0.023) but had no significant effect on the controlled attenuation parameter (CAP), other biochemical indicators (aminotransferases, total bilirubin, glucose and lipid parameters, hsCRP, SOD, and UA), physical measurements (DBP, SBP, BMI, WHR, BF%, and BMR), or APRI and FIB-4 indices. Gut microbiota analysis revealed increased species diversity and enrichment of Oscillospiraceae in the silymarin group. Conclusion These findings suggest that silymarin supplementation could improve liver stiffness in MASLD patients, possibly by modulating the gut microbiota. Trial registration The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2200059043).
- Published
- 2024
- Full Text
- View/download PDF
17. Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study
- Author
-
Larissa Nixdorf, Lukas Hartl, Stefanie Ströhl, Daniel Moritz Felsenreich, Magdalena Mairinger, Julia Jedamzik, Paula Richwien, Behrang Mozayani, Georg Semmler, Lorenz Balcar, Michael Schwarz, Mathias Jachs, Nina Dominik, Christoph Bichler, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Felix B. Langer, David Josef Maria Bauer, and Gerhard Prager
- Subjects
Bariatric surgery ,Metabolic surgery ,MASLD ,MASH ,Fibroscan ,Liver stiffness ,Medicine ,Science - Abstract
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) and related steatohepatitis (MASH) are common among obese patients and may improve after metabolic/bariatric surgery (MBS). 93 Patients undergoing MBS in 2021–2022 were prospectively enrolled. Liver stiffness measurement (LSM; via vibration-controlled transient elastography [VCTE], point [pSWE] and 2D [2DSWE] shear wave elastography) and non-invasive steatosis assessment (via controlled attenuation parameter [CAP]) were performed before (baseline [BL]) and three months (M3) after surgery. 93 patients (median age 40.9 years, 68.8% female, median BL-BMI: 46.0 kg/m2) were included. BL-liver biopsy showed MASLD in 82.8% and MASH in 34.4% of patients. At M3 the median relative total weight loss (%TWL) was 20.1% and the median BMI was 36.1 kg/m2. LSM assessed by VCTE and 2DSWE, as well as median CAP all decreased significantly from BL to M3 both in the overall cohort and among patients with MASH. There was a decrease from BL to M3 in median levels of ALT (34.0 U/L to 31 U/L; p = 0.025), gamma glutamyl transferase (BL: 30.0 to 21.0 U/L; p
- Published
- 2024
- Full Text
- View/download PDF
18. Isosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial).
- Author
-
Bigelow, Amee M., Riggs, Kyle W., Morales, David L. S., Opotowsky, Alexander R., Lubert, Adam M., Dillman, Jonathan R., Veldtman, Gruschen R., Heydarian, Haleh C., Trout, Andrew T., Cooper, David S., Goldstein, Stuart L., Chin, Clifford, Palermo, Joseph J., Ollberding, Nicholas J., Mays, Wayne A., and Alsaied, Tarek
- Subjects
- *
EXERCISE physiology , *AEROBIC capacity , *ANAEROBIC threshold , *VENOUS pressure , *EXERCISE intensity - Abstract
After Fontan operation, decreased venous capacitance and venoconstriction are adaptive mechanisms to maintain venous return and cardiac output. The consequent higher venous pressure may adversely impact end-organ function, exercise capacity and result in worse clinical outcomes. This pilot study evaluated the safety and effect of isosorbide dinitrate (ISDN), a venodilator, on exercise capacity, peripheral venous pressure (PVP), and liver stiffness in patients with Fontan circulation. In this prospective single-arm trial, 15 individuals with Fontan circulation were evaluated at baseline and after 4 weeks of therapeutic treatment with ISDN. Primary aims were to assess the safety of ISDN and the effect on maximal exercise. We also aimed to evaluate the effect of ISDN on ultrasound-assessed liver stiffness, markers of submaximal exercise, and PVP at rest and peak exercise. Repeated measures t-tests were used to assess change in variables of interest in response to ISDN. Mean age was 23.5 ± 9.2 years (range 11.2–39.0 years), and 10/15 (67%) were male. There was no statistically significant change in peak VO2 (1401 ± 428 to 1428 ± 436 mL/min, p = 0.128), but VO2 at the anaerobic threshold increased (1087 ± 313 to 1115 ± 302 mL/min, p = 0.03). ISDN was also associated with a lower peak exercise PVP (22.5 ± 4.5 to 20.6 ± 3.0 mmHg, p = 0.015). Liver stiffness was lower with ISDN, though the difference was not statistically significant (2.3 ± 0.4 to 2.1 ± 0.5 m/s, p = 0.079). Of the patients completing the trial, mild headache was common (67%), but there were no major adverse events. Treatment with ISDN for 4 weeks is well-tolerated in patients with a Fontan circulation. ISDN is associated with an increase in VO2 at anaerobic threshold, lower peak PVP, and a trend toward lower liver stiffness. Larger, longer duration studies will be necessary to define the impact of ISDN on clinical outcomes in the Fontan circulation. Clinical Trial Registration: URL: https://clinicaltrials.gov. Unique identifier: NCT04297241. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Response to semaglutide of non-drinker subjects with type 2 diabetes
- Author
-
Giovanni Petralli, Francesco Raggi, Alice Del Zoppo, Chiara Rovera, Antonio Salvati, Maurizia Rossana Brunetto, and Anna Solini
- Subjects
Interleukin-18 ,Liver stiffness ,Semaglutide ,Non-drinker ,Type 2 diabetes ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) displays a worse prognosis in subjects with type 2 diabetes (T2D); effective treatments are, so far, scanty. Semaglutide showed efficacy in improving steatohepatitis. We longitudinally observed a MASLD cohort of T2D subjects starting semaglutide, to detect an improvement of non-invasive surrogates of steatosis and fibro-inflammatory liver involvement, evaluating the role of mild alcohol consumption. Patients and methods In 62 overweight/obese T2D subjects with MASLD (36 non-drinker and 26 mild alcohol consumers), anthropometric, bio-humoral and transient elastography (TE) data were collected before (T0) and after an average time of 6.4 month (T1) from injective semaglutide prescription. Circulating levels of hormones (GIP, GLP-1, glucagon, insulin) and inflammatory markers (TNFα, MCP-1, IL-18, IL-10) were measured. Steatotic and necro-inflammatory liver involvement was evaluated with FibroScan controlled attenuation parameter (CAP) and liver stiffness (LS), respectively. Results Significant (p
- Published
- 2024
- Full Text
- View/download PDF
20. Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study
- Author
-
Hariklia Kranidioti, Konstantinos Zisimopoulos, Theodora Oikonomou, Theodoros Voulgaris, Spyros Siakavellas, Polixeni Agorastou, Melanie Deutsch, Christos Triantos, Ioannis Goulis, George Papatheodoridis, and Spilios Manolakopoulos
- Subjects
Liver stiffness ,Chronic hepatitis B ,TDF ,BMI ,Metabolic factors ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background Preventing disease progression and viral suppression are the main goals of antiviral therapy in chronic hepatitis B (CHB). Liver stiffness measurement (LSM) by transient elastography is a reliable non-invasive method to assess liver fibrosis in patients with CHB. Our aim was to explore factors that may affect changes in LSMs during long term tenofovir (TDF) monotherapy in a well characterized cohort of patients with compensated CHB. Methods We analyzed serial LSMs in 103 adult patients with CHB who were on TDF monotherapy and had at least three LSMs over a period of 90 months. Results Twenty-five (24%) patients had advanced fibrosis at baseline. A significant decline in mean LSM between baseline and last visit (8.7 ± 6.2 kPa vs. 6.7 ± 3.3, p = 10− 3) was observed. Twenty-four (23%) patients had progression of liver fibrosis with mean increase in liver stiffness of 2.8 kPa (range: 0.2–10.2 kPa). Multivariate analysis showed that BMI ≥ 25 (OR, 0.014; 95% CI, 0.001–0.157; p = 0.001) and advanced fibrosis (OR, 5.169; 95% CI, 1.240–21.540; p = 0.024) were independently associated with a fibrosis regression of > 30% of liver stiffness compared to baseline value. Conclusions In CHB patients TDF monotherapy resulted in liver fibrosis regression, especially in patients with advanced fibrosis. Despite the successful antiviral effect of TDF, 1 out of 4 patients had liver fibrosis progression. Obesity and advanced fibrosis at baseline were independently associated with significant liver fibrosis regression.
- Published
- 2024
- Full Text
- View/download PDF
21. The Impact of Silent Liver Disease on Hospital Length of Stay Following Isolated Coronary Artery Bypass Grafting Surgery.
- Author
-
Suffredini, Giancarlo, Le, Lan, Lee, Seoho, Gao, Wei Dong, Robich, Michael P., Aziz, Hamza, Kilic, Ahmet, Lawton, Jennifer S., Voegtline, Kristin, Olson, Sarah, Brown, Charles Hugh, Lima, Joao A. C., Das, Samarjit, and Dodd-o, Jeffrey M.
- Subjects
- *
CORONARY artery bypass , *LENGTH of stay in hospitals , *ACOUSTIC radiation force impulse imaging , *LIVER surgery , *LIVER diseases , *CARDIAC surgery - Abstract
Objectives: Risk assessment models for cardiac surgery do not distinguish between degrees of liver dysfunction. We have previously shown that preoperative liver stiffness is associated with hospital length of stay following cardiac surgery. The authors hypothesized that a liver stiffness measurement (LSM) ≥ 9.5 kPa would rule out a short hospital length of stay (LOS < 6 days) following isolated coronary artery bypass grafting (CABG) surgery. Methods: A prospective observational study of one hundred sixty-four adult patients undergoing non-emergent isolated CABG surgery at a single university hospital center. Preoperative liver stiffness measured by ultrasound elastography was obtained for each participant. Multivariate logistic regression models were used to assess the adjusted relationship between LSM and a short hospital stay. Results: We performed multivariate logistic regression models using short hospital LOS (<6 days) as the dependent variable. Independent variables included LSM (<9.5 kPa, ≥9.5 kPa), age, sex, STS predicted morbidity and mortality, and baseline hemoglobin. After adjusting for included variables, LSM ≥ 9.5 kPa was associated with lower odds of early discharge as compared to LSM < 9.5 kPa (OR: 0.22, 95% CI: 0.06–0.84, p = 0.03). The ROC curve and resulting AUC of 0.76 (95% CI: 0.68–0.83) suggest the final multivariate model provides good discriminatory performance when predicting early discharge. Conclusions: A preoperative LSM ≥ 9.5 kPa ruled out a short length of stay in nearly 80% of patients when compared to patients with a LSM < 9.5 kPa. Preoperative liver stiffness may be a useful metric to incorporate into preoperative risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Response to semaglutide of non-drinker subjects with type 2 diabetes.
- Author
-
Petralli, Giovanni, Raggi, Francesco, Zoppo, Alice Del, Rovera, Chiara, Salvati, Antonio, Brunetto, Maurizia Rossana, and Solini, Anna
- Subjects
- *
TYPE 2 diabetes , *SEMAGLUTIDE , *WAIST circumference , *ALCOHOL drinking - Abstract
Background: Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) displays a worse prognosis in subjects with type 2 diabetes (T2D); effective treatments are, so far, scanty. Semaglutide showed efficacy in improving steatohepatitis. We longitudinally observed a MASLD cohort of T2D subjects starting semaglutide, to detect an improvement of non-invasive surrogates of steatosis and fibro-inflammatory liver involvement, evaluating the role of mild alcohol consumption. Patients and methods: In 62 overweight/obese T2D subjects with MASLD (36 non-drinker and 26 mild alcohol consumers), anthropometric, bio-humoral and transient elastography (TE) data were collected before (T0) and after an average time of 6.4 month (T1) from injective semaglutide prescription. Circulating levels of hormones (GIP, GLP-1, glucagon, insulin) and inflammatory markers (TNFα, MCP-1, IL-18, IL-10) were measured. Steatotic and necro-inflammatory liver involvement was evaluated with FibroScan controlled attenuation parameter (CAP) and liver stiffness (LS), respectively. Results: Significant (p < 0.006) T0-T1 reductions of BMI, waist circumference, fasting glucose, and HbA1c were observed. AST (-10 ± 3 IU/L), ALT (-18 ± 5 IU/L), GGT (-33 ± 15 IU/L), CAP (-25 ± 8 dB/m) and LS (-0.8 ± 0.4 kPa) were reduced, too. GLP-1 increased (+ 95.9 pM, p < 0.0001) and IL-18 was reduced (-46.6 pg/ml, p = 0.0002). After adjustment for confounders, CAP improving was only related to GLP-1 increase (ß=-0.437, p = 0.0122). Mild alcohol intake did not influence these relations. Conclusion: Use of semaglutide in subjects with T2D and MASLD is associated with a significant decline of liver steatosis and necroinflammation proxies; mild alcohol assumption did not exert any influence. An independent effect of GLP-1 raise was observed on reduction of steatosis, irrespective of alcohol consumption. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol.
- Author
-
Fischer, Anja M., Lechea, Nazim, and Coxson, Harvey O.
- Subjects
- *
LIVER diseases , *MAGNETIC resonance imaging , *LIVER biopsy , *LIVER histology - Abstract
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a prevalent condition with a broad spectrum defined by liver biopsy. This gold standard method evaluates three features: steatosis, activity (ballooning and lobular inflammation), and fibrosis, attributing them to certain grades or stages using a semiquantitative scoring system. However, liver biopsy is subject to numerous restrictions, creating an unmet need for a reliable and reproducible method for MASLD assessment, grading, and staging. Noninvasive imaging modalities, such as magnetic resonance imaging (MRI), offer the potential to assess quantitative liver parameters. This review aims to provide an overview of the available MRI techniques for the three criteria evaluated individually by liver histology. Here, we discuss the possibility of combining multiple MRI parameters to replace liver biopsy with a holistic, multiparametric MRI protocol. In conclusion, the development and implementation of such an approach could significantly improve the diagnosis and management of MASLD, reducing the need for invasive procedures and paving the way for more personalized treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
- Author
-
Jachs, Mathias, Hartl, Lukas, Simbrunner, Benedikt, Semmler, Georg, Balcar, Lorenz, Hofer, Benedikt Silvester, Schwarz, Michael, Bauer, David, Stättermayer, Albert Friedrich, Pinter, Matthias, Trauner, Michael, Reiberger, Thomas, and Mandorfer, Mattias
- Subjects
- *
VENOUS pressure , *VON Willebrand factor , *PORTAL hypertension , *PATIENT portals , *PLATELET count , *PROGNOSIS - Abstract
Non-invasive tests to assess the probability of clinically significant portal hypertension (CSPH) – including the ANTICIPATE±NASH models based on liver stiffness measurement and platelet count±BMI, and the von Willebrand factor antigen to platelet count ratio (VITRO) – have fundamentally changed the management of compensated advanced chronic liver disease (cACLD). However, their prognostic utility has not been compared head-to-head to the gold standard for prognostication in cACLD, i.e. the hepatic venous pressure gradient (HVPG). Patients with cACLD (liver stiffness measurement ≥10 kPa) who underwent advanced characterization via same-day HVPG/non-invasive test assessment from 2007-2022 were retrospectively included. Long-term follow-up data on hepatic decompensation was recorded. Four hundred and twenty patients with cACLD of varying etiologies, with a CSPH prevalence of 67.6%, were included. The cumulative incidence of hepatic decompensation at 1 and 2 years was 4.7% and 8.0%, respectively. HVPG, VITRO, and ANTICIPATE±NASH-CSPH-probability showed similar time-dependent prognostic value (AUROCs 0.683-0.811 at 1 year and 0.699-0.801 at 2 years). In competing risk analyses adjusted for MELD score and albumin, HVPG (adjusted subdistribution hazard ratio [aSHR] 1.099 [95% CI 1.054–1.150] per mmHg; p < 0.001), or VITRO (aSHR 1.134 [95% CI 1.062–1.211] per unit; p < 0.001), or ANTICIPATE±NASH-CSPH-probability (aSHR 1.232 [95% CI 1.094–1.387] per 10%; p < 0.001) all predicted first decompensation during follow-up. Previously proposed cut-offs (HVPG ≥10 mmHg vs. <10 mmHg, VITRO ≥2.5 vs. < 2.5, and ANTICIPATE-CSPH probability ≥60% vs. < 60%) all accurately discriminated between patients at negligible risk and those at substantial risk of hepatic decompensation. The prognostic performance of ANTICIPATE±NASH-CSPH-probability and VITRO is comparable to that of HVPG, supporting their utility for identifying patients who may benefit from medical therapies to prevent first hepatic decompensation. Non-invasive tests have revolutionized the diagnosis and management of clinically significant portal hypertension in patients with compensated advanced chronic liver disease (cACLD). However, limited data exists regarding the prognostic utility of non-invasive tests in direct comparison to the gold standard for prognostication in cACLD, i.e. the hepatic venous pressure gradient. In our study including 420 patients with cACLD, the ANTICIPATE±NASH model and VITRO yielded similar AUROCs to hepatic venous pressure gradient for hepatic decompensation within 1 to 2 years. Thus, non-invasive tests should be applied and updated in yearly intervals in clinical routine to identify patients at short-term risk, thereby identifying patients who may benefit from treatment aimed at preventing hepatic decompensation. [Display omitted] • Non-invasive tests have similar prognostic utility to the hepatic venous pressure gradient in patients with cACLD. • ANTICIPATE±NASH and VITRO identify patients at short-term risk of decompensation. • Non-invasive tests may be applied to individualize prognosis and treatment decisions in cACLD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review.
- Author
-
Celsa, Ciro, Veneziano, Marzia, Di Giorgio, Francesca Maria, Cannova, Simona, Lombardo, Antonino, Errigo, Emanuele, Landro, Giuseppe, Simone, Fabio, Sinagra, Emanuele, and Calvaruso, Vincenza
- Subjects
NONINVASIVE diagnostic tests ,PORTAL hypertension ,PATIENT portals ,HYPERTENSION ,PLATELET count - Abstract
Clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease indicates an increased risk of decompensation and death. While invasive methods like hepatic venous–portal gradient measurement is considered the gold standard, non-invasive tests (NITs) have emerged as valuable tools for diagnosing and monitoring CSPH. This review comprehensively explores non-invasive diagnostic modalities for portal hypertension, focusing on NITs in the setting of hepatitis B and hepatitis C virus-related cirrhosis. Biochemical-based NITs can be represented by single serum biomarkers (e.g., platelet count) or by composite scores that combine different serum biomarkers with each other or with demographic characteristics (e.g., FIB-4). On the other hand, liver stiffness measurement and spleen stiffness measurement can be assessed using a variety of elastography techniques, and they can be used alone, in combination with, or as a second step after biochemical-based NITs. The incorporation of liver and spleen stiffness measurements, alone or combined with platelet count, into established and validated criteria, such as Baveno VI or Baveno VII criteria, provides useful tools for the prediction of CSPH and for ruling out high-risk varices, potentially avoiding invasive tests like upper endoscopy. Moreover, they have also been shown to be able to predict liver-related events (e.g., the occurrence of hepatic decompensation). When transient elastography is not available or not feasible, biochemical-based NITs (e.g., RESIST criteria, that are based on the combination of platelet count and albumin levels) are valid alternatives for predicting high-risk varices both in patients with untreated viral aetiology and after sustained virological response. Ongoing research should explore novel biomarkers and novel elastography techniques, but current evidence supports the utility of routine blood tests, LSM, and SSM as effective surrogates in diagnosing and staging portal hypertension and predicting patient outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study.
- Author
-
Kranidioti, Hariklia, Zisimopoulos, Konstantinos, Oikonomou, Theodora, Voulgaris, Theodoros, Siakavellas, Spyros, Agorastou, Polixeni, Deutsch, Melanie, Triantos, Christos, Goulis, Ioannis, Papatheodoridis, George, and Manolakopoulos, Spilios
- Subjects
- *
CHRONIC hepatitis B , *HEPATIC fibrosis , *TENOFOVIR , *LIVER , *ELASTOGRAPHY - Abstract
Background: Preventing disease progression and viral suppression are the main goals of antiviral therapy in chronic hepatitis B (CHB). Liver stiffness measurement (LSM) by transient elastography is a reliable non-invasive method to assess liver fibrosis in patients with CHB. Our aim was to explore factors that may affect changes in LSMs during long term tenofovir (TDF) monotherapy in a well characterized cohort of patients with compensated CHB. Methods: We analyzed serial LSMs in 103 adult patients with CHB who were on TDF monotherapy and had at least three LSMs over a period of 90 months. Results: Twenty-five (24%) patients had advanced fibrosis at baseline. A significant decline in mean LSM between baseline and last visit (8.7 ± 6.2 kPa vs. 6.7 ± 3.3, p = 10− 3) was observed. Twenty-four (23%) patients had progression of liver fibrosis with mean increase in liver stiffness of 2.8 kPa (range: 0.2–10.2 kPa). Multivariate analysis showed that BMI ≥ 25 (OR, 0.014; 95% CI, 0.001–0.157; p = 0.001) and advanced fibrosis (OR, 5.169; 95% CI, 1.240–21.540; p = 0.024) were independently associated with a fibrosis regression of > 30% of liver stiffness compared to baseline value. Conclusions: In CHB patients TDF monotherapy resulted in liver fibrosis regression, especially in patients with advanced fibrosis. Despite the successful antiviral effect of TDF, 1 out of 4 patients had liver fibrosis progression. Obesity and advanced fibrosis at baseline were independently associated with significant liver fibrosis regression. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Comparison between Fibroscan and Hepatus for Detecting NAFLD in Patients with Metabolic Dysregulation.
- Author
-
Jie-Hui Sun, Ping-Ping Zhang, Kun Wang, Miao Xu, Jing Sun, and Li Li
- Subjects
- *
NON-alcoholic fatty liver disease , *RECEIVER operating characteristic curves , *FATTY liver , *PEARSON correlation (Statistics) , *SCATTER diagrams - Abstract
Background The clinical application of the innovative instantaneous elasticity technology is currently in the evaluation stage. This study aimed to compare the detection performance of Fibroscan and Hepatus in detecting nonalcoholic fatty liver disease (NAFLD) among patients with metabolic dysregulation. Methods This prospective study was conducted between January 2021 and April 2021 with 149 patients enrolled. Clinical data were collected, and all patients underwent both Fibroscan and Hepatus to determine liver stiffness measurement (LSM) and attenuation parameters. Pearson correlation analysis and scatter diagram were used to analyze the correlation, while a paired t-test was used to compare the differences between the detected values from the two machines. Receiver operating characteristic curves (ROC) were constructed to compare the diagnostic cut-off for Hepatic Steatosis Index (HSI)-based NAFLD. Results The detection success rate of Hepatus (100.0%) was higher than that of Fibroscan (96.0%). And we found that the LSM (r = 0.663, P<0.001) and attenuation parameters (r = 0.778, P<0.001) obtained by Fibroscan and Hepatus were significantly correlated. Hepatus tended to produce a higher LSM value (Hepatus vs. Fibroscan: 6.04 vs. 5.66 kPa, P=0.016), but a lower attenuation parameter value than Fibroscan (Hepatus vs. Fibroscan: 264 vs. 277 dB/m, P<0.001). The area under the ROC curve for detecting HSI-based NAFLD was 0.811 for Fibroscan and 0.832 for Hepatus. Conclusion Measurements obtained by Fibroscan and Hepatus are highly correlated, and the diagnostic value of the two TE devices is comparable in detecting HSI-based NAFLD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
28. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
- Author
-
Con, Danny, Tu, Steven, Clayton-Chubb, Daniel, Lubel, John S., Nicoll, Amanda J., Sawhney, Rohit, and Bloom, Stephen
- Subjects
- *
CHRONIC hepatitis B , *LIVER diseases , *HEPATIC fibrosis , *FATTY liver , *FIBROSIS - Abstract
Background & Aims: Concurrent hepatic steatosis has diverse effects on chronic hepatitis B (CHB), however the combined effects of metabolic dysfunction-associated steatotic liver disease (MASLD) and CHB on liver fibrosis progression remains unclear. The primary aim of this study was to utilize serial fibrosis measurements to compare the dynamic change in fibrosis in CHB patients with/without concurrent MASLD. The secondary aim was to investigate factors associated with steatosis development and regression in CHB patients. Methods: This was a retrospective cohort study of all non-cirrhotic CHB patients identified from 1/1/2011 to 31/12/2016. Hepatic steatosis was diagnosed by ultrasound. Fibrosis markers included liver stiffness (LSM) by transient elastography, APRI and FIB-4. General linear mixed effects modelling was used to fit polynomial and linear estimates. Results: Of 810 CHB patients (n = 2,373 LSM measurements; median age 44.4y; 48% male; 24% HBeAg positive), 14% had concurrent MASLD. LSM was higher at baseline but decreased in MASLD patients over time, while LSM remained stable in non-MASLD patients, such that all patients had similar LSM beyond 4–5 years. MASLD patients had lower APRI compared to non-MASLD patients, which was predominately due to a higher platelet count and higher ALT over time. There was substantial discordance between LSM, APRI and FIB-4. Baseline BMI was the only factor that predicted steatosis development and regression. Conclusions: We found no evidence of an association between concurrent MASLD and fibrosis progression amongst CHB patients without baseline advanced liver disease. APRI and FIB-4 may have reduced accuracy in MASLD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Prognostic Indicators of Overall Survival in Hepatocellular Carcinoma Patients Undergoing Liver Resection.
- Author
-
Ursu, Cristina-Paula, Ciocan, Andra, Ursu, Ștefan, Ciocan, Răzvan Alexandru, Gherman, Claudia Diana, Cordoș, Ariana-Anamaria, Vălean, Dan, Pop, Rodica Sorina, Furcea, Luminița Elena, Procopeț, Bogdan, Ștefănescu, Horia, Moiș, Emil Ioan, Al Hajjar, Nadim, and Graur, Florin
- Subjects
- *
ALPHA fetoproteins , *CIRRHOSIS of the liver , *RESEARCH funding , *SCIENTIFIC observation , *CANCER patients , *TUMOR markers , *MULTIVARIATE analysis , *DESCRIPTIVE statistics , *SURVIVAL analysis (Biometry) , *HEPATOCELLULAR carcinoma , *OVERALL survival - Abstract
Simple Summary: Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related deaths worldwide, with liver resection being the most effective for curative intent. The hepatic venous pressure gradient (HVPG), transient elastography-liver stiffness measurement (TE-LSM), and TAC score are intricately connected with the postoperative evolution of cirrhosis. The primary objective of our study is to evaluate the predictive value of key parameters for surgical patients. The proposed predictors can better presume treatment outcomes in HCC and potentially allow an improvement in therapeutic strategy. Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and the third contributor to malignancy-related deaths worldwide. The hepatic venous pressure gradient (HVPG), transient elastography-liver stiffness measurement (TE-LSM), and the association between TBS (tumor burden score), alpha-fetoprotein levels, and the Child–Pugh classification (TAC score) can serve as valuable prognostic indicators for these patients. Therefore, the main objective of our research was to analyze the prognostic value of the HVPG, TE-LSM, TBS, and TAC scores. An observational and survival study was conducted on 144 subjects. Our findings indicated that HVPG greater than 10 mmHg, AFP surpassing 400 ng/mL, an advanced C–P class, and low TAC score are independent predictors of overall survival. During the multivariate analysis, AFP serum levels and C–P class proved statistically significant. The present study revealed significant differences in overall survival between the two groups divided upon HVPG values and settled by the cutoff of 10 mmHg (p = 0.02). Moreover, by dividing the cohort into three groups based on the TAC score (very low, low, and moderate), statistically significant differences in overall survival were observed across the groups (p = 0.004). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Association between composite dietary antioxidant index and metabolic dysfunction associated steatotic liver disease: result from NHANES, 2017-2020
- Author
-
Zhaofu Zhang, Hao Wang, and Youpeng Chen
- Subjects
metabolic dysfunction associated steatotic liver disease ,composite dietary antioxidant index ,oxidative stress ,liver stiffness ,restricted cubic spline ,Nutrition. Foods and food supply ,TX341-641 - Abstract
BackgroundThe development of metabolic dysfunction associated steatotic liver disease (MASLD) has been associated with lipid accumulation, oxidative stress, endoplasmic reticulum stress, and lipotoxicity. The Composite Dietary Antioxidant Index (CDAI) is a comprehensive score representing an individual intake of various dietary antioxidants, including vitamin A, vitamin C, vitamin E, selenium, zinc, and carotenoids. This study investigated the association between CDAI and MASLD.Materials and methodsClinical and demographic data, as well as ultrasound transient elastography measurements at baseline, were collected from the National Health and Nutrition Examination Survey 2017–2020 (NHANES 2017–2020). The controlled attenuation parameter was utilized to diagnose the presence of hepatic steatosis and to categorize individuals into those with and without MASLD. Liver stiffness was measured by ultrasound transient elastography, and subjects were classified as those with and without advanced liver fibrosis.ResultsThis study included 5,884 adults, of whom 3,433 were diagnosed with MASLD, resulting in a weighted prevalence of 57.3%. After adjusting for covariates, the odds ratios for MASLD were 0.96 (95% CI: 0.82, 1.12) in the second quartile, 0.80 (95% CI: 0.68, 0.95) in the third quartile and 0.60 (95% CI: 0.49, 0.73) in the fourth quartile, respectively. CDAI, however, was not significantly associated with advanced liver fibrosis.ConclusionThese findings suggested that scores on the CDAI were linearly and negatively associated with the prevalence of MASLD in the United States adults.
- Published
- 2024
- Full Text
- View/download PDF
31. Prevalence and factors associated with liver fibrosis among first‐degree relatives of Mexican Americans with hepatocellular carcinoma
- Author
-
Sharpton, Suzanne, Shan, Kuangda, Bettencourt, Ricki, Lee, Miryoung, McCormick, Joseph B, Fisher‐Hoch, Susan P, and Loomba, Rohit
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Digestive Diseases ,Liver Cancer ,Liver Disease ,Chronic Liver Disease and Cirrhosis ,Rare Diseases ,Diabetes ,Cancer ,Nutrition ,Adult ,Humans ,Female ,Middle Aged ,Male ,Carcinoma ,Hepatocellular ,Mexican Americans ,Non-alcoholic Fatty Liver Disease ,Cohort Studies ,Prospective Studies ,Prevalence ,Cross-Sectional Studies ,Liver Neoplasms ,Liver Cirrhosis ,Elasticity Imaging Techniques ,Liver ,elastography ,familial risk ,fatty liver ,fibrosis ,liver stiffness ,Clinical Sciences ,Pharmacology and Pharmaceutical Sciences ,Gastroenterology & Hepatology ,Clinical sciences ,Pharmacology and pharmaceutical sciences - Abstract
Background and aimsWhether hepatocellular carcinoma (HCC) increases the familial risk for hepatic fibrosis has not been thoroughly explored, particularly in Mexican Americans who are disproportionately affected by obesity and metabolic syndrome. We evaluated the risk of significant hepatic fibrosis in first-degree relatives of Mexican American adults with HCC.MethodsWe performed a cross-sectional analysis of a prospective cohort of Mexican American probands with HCC and first-degree relatives enrolled in the Hispanic Liver Cancer Cohort study. We evaluated the prevalence of hepatic fibrosis in first-degree relatives, defined by liver stiffness measurement (LSM) >= 7.0 kPa with transient elastography (TE). Secondary outcomes included the prevalence of definite hepatic steatosis, defined by controlled attenuation parameter >=288 dB/m.ResultsWe identified 70 probands diagnosed with HCC; 47% were female and the mean age was 62 years (±13 years). Among 112 first-degree relatives with a mean age of 43 years (±14 years), 19 (17%) had significant fibrosis and 47 (42%) had definite hepatic steatosis, respectively. The prevalence of significant fibrosis was 20% in first-degree relatives 40 years of age or older. Regression analysis revealed that diabetes (OR 3.2, 95% CI: 1.1-9.2, p = 0.03) and aspartate aminotransferase >=30 units/L (OR 4.0, 95% CI: 1.4-11.7, p = 0.01) were predictors of significant fibrosis in first-degree relatives.ConclusionsUsing a well-phenotyped familial cohort, we found that the prevalence of significant fibrosis and definite hepatic steatosis are high in first-degree relatives of Mexican Americans with HCC, particularly those with diabetes, suggesting that this population may benefit from screening for liver disease.
- Published
- 2023
32. Liver stiffness as a prognostic parameter and tool for risk stratification in advanced cardiac transthyretin amyloidosis
- Author
-
Ihne-Schubert, Sandra Michaela, Morbach, Caroline, Goetze, Oliver, Cejka, Vladimir, Steinhardt, Maximilian Johannes, Frantz, Stefan, Einsele, Hermann, Sommer, Claudia, Störk, Stefan, Schubert, Torben, and Geier, Andreas
- Published
- 2024
- Full Text
- View/download PDF
33. Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis
- Author
-
Brunger, Anne F., Tingen, Hendrea S.A., Bijzet, Johan, van Rheenen, Ronald, Blokzijl, Hans, Roeloffzen, Wilfried W. H., Houwerzijl, Ewout J., Muntinghe, Friso L. H., Slart, Riemer H. J. A., Gans, Reinold O. B., Kimmich, Christoph, Hazenberg, Bouke P. C., and Nienhuis, Hans L. A.
- Published
- 2024
- Full Text
- View/download PDF
34. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment
- Author
-
Tobaruela-Resola, Ana Luz, Milagro, Fermín I., Elorz, Mariana, Benito-Boillos, Alberto, Herrero, José I., Mogna-Peláez, Paola, Tur, Josep A., Martínez, J. Alfredo, Abete, Itziar, and Zulet, M. Ángeles
- Published
- 2024
- Full Text
- View/download PDF
35. Advanced fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis
- Author
-
Takashi Kumada, Hidenori Toyoda, Sadanobu Ogawa, Tatsuya Gotoh, Yasuaki Suzuki, Kento Imajo, Katsutoshi Sugimoto, Tatsuya Kakegawa, Hidekatsu Kuroda, Yutaka Yasui, Nobuharu Tamaki, Masayuki Kurosaki, Namiki Izumi, Tomoyuki Akita, Junko Tanaka, and Atsushi Nakajima
- Subjects
hepatic steatosis ,attenuation coefficient ,mr elastography ,mri-derived proton density fat fraction ,liver stiffness ,Medical technology ,R855-855.5 - Abstract
Purpose The effect of hepatic fibrosis stage on quantitative ultrasound based on the attenuation coefficient (AC) for liver lipid quantification is controversial. The objective of this study was to determine how the degree of fibrosis assessed by magnetic resonance (MR) elastography affects AC based on the ultrasound-guided attenuation parameter according to the grade of hepatic steatosis, using magnetic resonance imaging (MRI)–derived proton density fat fraction (MRI-derived PDFF) as the reference standard. Methods Between February 2020 and April 2021, 982 patients with chronic liver disease who underwent AC and MRI-derived PDFF measurement as well as MR elastography were enrolled. Multiple regression was used to investigate whether AC was affected by the degree of liver stiffness. Results AC increased as liver stiffness progressed in 344 patients without hepatic steatosis (P=0.009). In multivariable analysis, AC was positively correlated with skin-capsule distance (P
- Published
- 2024
- Full Text
- View/download PDF
36. Cardio-Hepatic Interaction in Cardiac Amyloidosis.
- Author
-
Ihne-Schubert, Sandra Michaela, Goetze, Oliver, Gerstendörfer, Felix, Sahiti, Floran, Schade, Ina, Papagianni, Aikaterini, Morbach, Caroline, Frantz, Stefan, Einsele, Hermann, Knop, Stefan, Sommer, Claudia, Müllhaupt, Beat, Schubert, Torben, Störk, Stefan, and Geier, Andreas
- Subjects
- *
CARDIAC amyloidosis , *HEPATIC fibrosis , *BLOOD flow , *BREATH tests , *MAXIMAL functions - Abstract
Background: Congestion is associated with poor prognosis in cardiac amyloidosis (CA). The cardio-hepatic interaction and the prognostic impact of secondary liver affection by cardiac congestion in CA are poorly understood and require further characterisation. Methods: Participants of the amyloidosis cohort study AmyKoS at the Interdisciplinary Amyloidosis Centre of Northern Bavaria with proven transthyretin (ATTR-CA) and light chain CA (AL-CA) underwent serial work-up including laboratory tests, echocardiography, and in-depth hepatic assessment by vibration-controlled transient elastography (VCTE) and 13C-methacetin breath test. Results: In total, 74 patients with AL-CA (n = 17), ATTR-CA (n = 26) and the controls (n = 31) were analysed. ATTR-CA patients showed decreased microsomal liver function expressed by maximal percentage of dose rate (PDRpeak) related to hepatic congestion. Reduced PDRpeak in AL-CA could result from altered pharmacokinetics due to changed hepatic blood flow. Liver stiffness as a combined surrogate of chronic liver damage and congestion was identified as a predictor of all-cause mortality. Statistical modelling of the cardio-hepatic interaction revealed septum thickness, NT-proBNP and PDRpeak as predictors of liver stiffness in both CA subtypes; dilatation of liver veins and the fibrosis score FIB-4 were only significant for ATTR-CA. Conclusions: Non-invasive methods allow us to characterise CA-associated hepatic pathophysiology. Liver stiffness might be promising for risk stratification in CA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma.
- Author
-
Stasi, Cristina and Brillanti, Stefano
- Subjects
- *
HEPATOCELLULAR carcinoma , *HEPATIC fibrosis , *PROGNOSIS , *ETIOLOGY of cancer , *LIVER cancer - Abstract
Globally, liver cancer is the third most frequent etiology of cancer death, with the rates of occurrence of both new cases and mortality estimated to increase. Given the availability of multiple treatments, interdisciplinary management of the patient is crucial. Moreover, the diagnostic assessment of patients with severe liver fibrosis is essential for the staging of HCC and liver cirrhosis and early diagnosis of HCC. In this context, non-invasive evaluation plays a critical role in identifying prognostic factors of clinical application for the surveillance of the occurrence or recurrence of HCC. The new frontiers of transient elastography have become a useful tool to assess the risk of HCC occurrence and recurrence. There has been a major increase in studies investigating the cutoff liver stiffness value that best predicts the need for monitoring for the onset of HCC. Therefore, this review discusses the new advances that have occurred in the last four years on HCC, highlighting the new frontiers of non-invasive evaluation of HCC subjects, with particular attention regarding the clinical application of liver stiffness assessment for de novo HCC and predicting recurrence in patients with chronic HCV achieving sustained virological response after treatment with direct antiviral agents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Comparison of spin-echo echo planar imaging and gradient-recalled echo sequences in magnetic resonance elastography of liver at 1.5T same MRI scanner.
- Author
-
Abe, Ryouna, Fukuzawa, Kei, Yoshihara, Chiharu, Tano, Masakatsu, and Saitoh, Satoshi
- Subjects
- *
ECHO-planar imaging , *MAGNETIC resonance , *ELECTRONIC health records , *SCANNING systems , *OPTICAL scanners , *MAGNETIC resonance imaging - Abstract
Purpose: Magnetic resonance elastography (MRE) is used to measure liver stiffness with gradient-recalled echo (GRE)-based and spin-echo echo planar imaging (SE-EPI)-based sequences. We compared the liver stiffness (LS) values of the two sequences on a 1.5-T MR imaging scanner. Methods: This is a retrospective study. An MRE imaging section was obtained from a horizontal section of the liver. Region of interest was drawn on the elastogram, and the mean LS and pixel values were measured and compared. The correlations between proton density fat fraction, R2* values, and biochemical data from electronic medical records were confirmed, and multivariate analysis was performed. Results: The mean LS values were 3.01 ± 1.78 kPa for GRE and 3.13 ± 1.57 kPa for SE-EPI, showing excellent agreement and a strong correlation between the two sequences (correlation coefficient r = 0.96). The mean pixel values were 369.5 ± 142.7 pixels for GRE and 490.1 ± 197.9 pixels for SE-EPI, showing a significant difference by the Wilcoxon rank sum test (p < 0.01). There were no LS unmeasurable cases in SE-EPI, but seven (2.5%) were unmeasurable in GRE, and multivariate analysis showed a significant difference with p < 0.001 in R2* values (mean, 92.7 Hz) for the GRE method. Conclusion: The GRE and SE-EPI methods were comparable for LS measurements in 1.5-T liver MRE, indicating that SE-EPI MRE is more useful because GRE MRE may not measure cases with high R2* values and the region of interest tends to be smaller. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Relationship between echocardiographic parameters and ALBI score in patients with rheumatic mitral stenosis.
- Author
-
Bedir, Ömer, Evlice, Mert, and Kurt, İbrahim H.
- Abstract
An increase in the volume and pressure of the heart chambers has been shown to increase liver stiffness. The Albumin-Bilirubin (ALBI) score is useful and easy-to-use for objectively assessing liver function. There is no information in the literature regarding changes in ALBI scores in patients with rheumatic mitral stenosis (MS). The aim of our study was to investigate changes in ALBI score and its clinical impact in patients with MS. Of the 247 patients analyzed, 54 were excluded from the study. The remaining 193 patients with MS were divided into two groups: Group I (64 patients with mitral valve area > 1.5 cm
2 and mean transmitral gradient < 10 mmHg) and Group II (129 patients with mitral valve area ≤ 1.5 cm2 and mean transmitral gradient ≥ 10 mmHg). The ALBI score was calculated based on serum albumin and total bilirubin levels using the following formula: ALBI= (log10 bilirubin [µmol/L] × 0.66) + (albumin [g/L] × − 0.085). A significant correlation was found between the ALBI score and mitral valve area in patients with MS (r = − 0.479, p < 0.001*) (Table 4; Fig. 3A). An ALBI score greater than − 2.61 was associated with severe MS (mitral valve area < 1.5 cm2 ), with a sensitivity of 72% and a specificity of 69% (Area under the ROC curve = 0.726; p < 0.001; 95% CI 0.650–0.802) (Fig. 4A). A significant correlation was found between the ALBI score and mean transmitral gradient in patients with MS (r = 0.476; p < 0.001*) (Table 4; Fig. 3B). An ALBI score greater than − 2.57 was associated with severe MS (mean transmitral gradient < 10 mmHg), with a sensitivity of 65% and a specificity of 67% (Area under the ROC curve = 0.684; p < 0.001; 95% CI 0.608–0.759) (Fig. 4B). In multivariate linear regression analysis, mitral valve area and mean transmitral gradient were significantly associated with increased ALBI scores (p < 0.05). Mitral valve area, mean transmitral gradient, and NT-proBNP levels were significantly associated with the ALBI score. The ALBI score could provide an information about the severity of MS. The ALBI score is a simple, evidence-based, objective, and discriminatory method for assessing liver function in patients with MS.Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary.Authors and their respective affiliations are correctly identified. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
40. Liver stiffness as a cornerstone in heart disease risk assessment.
- Author
-
Boeckmans, Joost, Sandrin, Laurent, Knackstedt, Christian, and Schattenberg, Jörn M.
- Subjects
- *
HEART diseases , *HEART disease related mortality , *CORONARY disease , *ARRHYTHMIA , *HEPATIC fibrosis , *LIVER - Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) typically presents with hepatic fibrosis in advanced disease, resulting in increased liver stiffness. A subset of patients further develops liver cirrhosis and hepatocellular carcinoma. Cardiovascular disease is a common comorbidity in patients with MASLD and its prevalence is increasing in parallel. Recent evidence suggests that especially liver stiffness, whether or not existing against a background of MASLD, is associated with heart diseases. We conducted a narrative review on the role of liver stiffness in the prediction of highly prevalent heart diseases including heart failure, cardiac arrhythmias (in particular atrial fibrillation), coronary heart disease, and aortic valve sclerosis. Research papers were retrieved from major scientific databases (PubMed, Web of Science) until September 2023 using 'liver stiffness' and 'liver fibrosis' as keywords along with the latter cardiac conditions. Increased liver stiffness, determined by vibration-controlled transient elastography or hepatic fibrosis as predicted by biomarker panels, are associated with a variety of cardiovascular diseases, including heart failure, atrial fibrillation, and coronary heart disease. Elevated liver stiffness in patients with metabolic liver disease should lead to considerations of cardiac workup including N-terminal pro-- B-type natriuretic peptide/B-type natriuretic peptide determination, electrocardiography, and coronary computed tomography angiography. In addition, patients with MASLD would benefit from heart disease case-finding strategies in which liver stiffness measurements can play a key role. In conclusion, increased liver stiffness should be a trigger to consider a cardiac workup in metabolically compromised patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Evolving portal hypertension through Baveno VII recommendations.
- Author
-
Mendizabal, Manuel, Lopes Cançado, Guilherme Grossi, and Albillos, Agustín
- Abstract
The Baveno VII consensus workshop has provided several novel recommendations regarding the management of patients with clinically significant portal hypertension (CSPH). The expert panel summarized the existing data into simple clinical rules to aid clinicians in their clinical practice. The use of non-invasive tests (NITs), especially liver stiffness measurement (LSM), have gain an important role in daily practice. The use of LSM alone or in combination with platelet count can be used to rule-in and rule-out compensated advanced chronic liver disease (cACLD) and CSPH. Further decompensation events were defined as a prognostic stage associated with an even higher mortality than that associated with first decompensation. Moreover, the term hepatic recompensation was introduced in Baveno VII consensus implying a partial or complete regression of the functional and structural changes of cirrhosis after the removal of the underlying etiology. This review will summarize the reader main aspects of Baveno VII consensus regarding the use of NITs in cACLD, analyze further decompensation events, and evaluate recent recommendations for prophylaxis and management of liver decompensation events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Confounders of Serum Phosphatidylethanol: Role of Red Blood Cell Turnover and Cirrhosis
- Author
-
Bartel M, Hofmann V, Wang S, Mueller J, Sundermann TR, and Mueller S
- Subjects
ethyl glucuronide ,ethyl sulfate ,alcohol-related liver disease ,liver fibrosis ,liver stiffness ,alcohol consumption ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Marc Bartel,1,* Vanessa Hofmann,1,* Shijin Wang,2,3 Johannes Mueller,2 Tom R Sundermann,1 Sebastian Mueller2 1Institute of Forensic and Traffic Medicine, Heidelberg University Hospital, Heidelberg, Germany; 2Center for Alcohol Research, University Hospital Heidelberg, Heidelberg, Germany; 3Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Shandong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Sebastian Mueller, Center for Alcohol Research, University Hospital Heidelberg, Im Neuenheimer Feld 350, Heidelberg, 69120, Germany, Tel +49 (0) 6221 567121, Email sebastian.mueller@urz.uni-heidelberg.dePurpose: Ethyl glucuronide (EtG), ethyl sulfate (EtS) and phosphatidylethanol (PEth) are considered specific direct biomarkers for detecting alcohol consumption. However, PEth, which is produced in red blood cells (RBC), varies considerably between patients for unknown reasons. We here studied various confounders of PEth elimination including fibrosis after alcohol withdrawal.Patients and Methods: EtG, EtS and PEth together with routine laboratory and clinical parameters were studied in 100 Caucasian heavy drinkers prior and after alcohol detoxification. In addition, fibrosis stage and degree of steatosis were assessed by transient elastography (Fibroscan, Echosens, Paris).Results: All three biomarkers were highly correlated (0.61– 0.72) with initial serum alcohol levels, but only PEth correlated with daily alcohol consumption. After alcohol withdrawal, PEth significantly decreased within 6.1 days from 1708 to 810 ng/mL (half-life varied from 1.6 to 15.2 days). Both levels of serum alcohol but also EtG and EtS were higher in patients with liver cirrhosis as compared to patients without fibrosis despite comparable alcohol consumption suggesting a decreased alcohol elimination in patients with cirrhosis. PEth was also elevated in cirrhosis but not significantly. In contrast, PEth elimination rate was significantly higher in patients with enhanced RBC turnover and signs of alcohol-mediated hemolytic anemia with elevated ferritin, LDH and increased mean corpuscular volume (MCV).Conclusion: We here demonstrate that alcohol elimination is decreased in patients with liver cirrhosis. In patients with cirrhosis, PEth levels are both affected in opposite directions by enhanced red blood cell turnover and elevated alcohol levels. Our data have important implications for the use and interpretation of PEth in the clinical setting.Keywords: ethyl glucuronide, ethyl sulfate, alcohol-related liver disease, liver fibrosis, liver stiffness, alcohol consumption
- Published
- 2023
43. Liver structure and fibrosis markers in modeling alcohol-induced liver injury and correction of detected disorders
- Author
-
V.I. Didenko, I.A. Klenina, O.I. Hrabovska, Yu.A. Gaidar, O.O. Halinskyi, V.A. Karachynova, and D.F. Mylostуva
- Subjects
fibrosis ,chronic liver damage ,hydroxyproline ,glycosaminoglycans ,liver stiffness ,morphological studies ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background. Chronic alcohol use leads to alcoholic liver fibrosis. Today, a sufficient number of scientific studies are focused on the pathometabolic mechanisms of liver fibrosis development and formation in animal models. The purpose of our study was to investigate structural changes and liver stiffness, biochemical markers of fibrosis in rats with chronic alcoholic liver injury (CALI) modeling and to evaluate the changes of these parameters with different types of treatment. Materials and methods. Eighty-nine rats were divided into experimental groups depending on the duration of alcohol exposure (4 and 12 weeks) and the corresponding type of correction (metadoxine and prebiotic). Results. When modeling CALI at week 4, morphological studies revealed moderate large-droplet fatty hepatosis and mild fibrosis in the central venule of the liver lobes. After 12 weeks of forced alcoholization, with more pronounced general intoxication, hepatocytes have dystrophic changes such as appearance of single or grouped dystrophic cells in the parenchyma. A combination of protein and fatty dystrophy was more common. Elastography allowed to detect structural changes in the liver at the early stages of fibrosis formation when modeling CALI for 12 weeks. There were also changes in the levels of biochemical parameters: free and protein-bound hydroxyproline, glycosaminoglycans. According to the results of elastography, liver stiffness in rats increased maximally after prebiotic correction in all approaches compared to the controls. After correction of CALI, both early- and long-term, fibrosis markers normalized in rat liver homogenate after administration of metadoxine and prebiotic. After prebiotic correction at week 12 of alcoholization, we observed a 12% decrease in liver parenchymal stiffness in the CALI modeling group and a 19% decrease (p
- Published
- 2023
- Full Text
- View/download PDF
44. Poor correlation of 2D shear wave elastography and transient elastography in Fontan‐associated liver disease: A head‐to‐head comparison
- Author
-
Madeleine Gill, Sanjivan Mudaliar, David Prince, Nwe Ni Than, Rachel Cordina, and Avik Majumdar
- Subjects
cirrhosis ,echocardiography ,elastography ,fibrosis ,Fontan ,liver stiffness ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background and Aims Fontan‐associated liver disease (FALD) is a long‐term complication of the Fontan procedure. Guidelines recommend elastography, but the utility of transient elastography (TE) and two‐dimensional shear wave elastography (2D SWE) is unknown. We aimed to evaluate the relationship between TE and 2D SWE in FALD. Methods This prospective cohort study included 25 patients managed in a specialist clinic between January 2018 and August 2021. Trained clinicians performed 2D SWE (GE Logiq‐E9) and TE (FibroScan 503 Touch) on the same day under the same conditions. Laboratory, echocardiography, and imaging data were collected. The atrioventricular systolic‐to‐diastolic duration (AVV S/D ratio) was calculated as a measure of cardiac diastolic function. Results We analyzed 40 paired measurements. Median age was 22 years. Median liver stiffness measurement (LSM) was 15.4 kPa (12.1–19.6) by TE and 8.0 kPa (7.0–10.3) (P = 0.001) by 2D SWE. There was weak correlation between the modalities (r = 0.41, P = 0.004). There was no correlation between time since Fontan and LSM by TE (r = 0.15, P = 0.19) or 2D SWE (r = 0.19, P = 0.13). There was no difference in LSM irrespective of whether sonographic cirrhosis was present or absent by TE (17.4 kPa [15.9–23.6] vs. 14.9 kPa [12.0–19.4], respectively, P = 0.6) or 2D SWE (9.0 kPa [2.8–10.5] vs. 8.0 kPa [6.7–10.1], P = 0.46). There was no correlation between AVV S/D ratio and LSM by TE (r = 0.16, P = 0.18) or 2D SWE (r = 0.02, P = 0.45). Conclusions In FALD, TE and 2D SWE are poorly correlated. LSM by either modality was not associated with known risk factors for liver fibrosis or Fontan function. Based on these data, the role of elastography in FALD is uncertain.
- Published
- 2023
- Full Text
- View/download PDF
45. Redox Homeostasis and Non-Invasive Assessment of Significant Liver Fibrosis by Shear Wave Elastography
- Author
-
Anna Egresi, Anna Blázovics, Gabriella Lengyel, Adrienn Gréta Tóth, Barbara Csongrády, Zsuzsanna Jakab, and Krisztina Hagymási
- Subjects
chronic liver diseases ,liver cirrhosis ,liver stiffness ,cytokines ,leptin ,adiponectin ,Medicine (General) ,R5-920 - Abstract
Hepatic fibrosis with various origins can be estimated non-invasively by using certain biomarkers and imaging-based measurements. The aim of our study was to examine redox homeostasis biomarkers and liver stiffness measurements for the assessment of significant liver fibrosis in different etiologies of chronic liver diseases. A cohort study consisting of 88 chronic liver disease patients of both sexes (age 49.1 ± 14.7 years) was performed. Cytokine profiles as well as redox homeostasis characteristics were determined. Liver fibrosis stages were assessed with shear wave elastography. The plasma levels of four cytokines showed no significant alteration between the four fibrotic stages; however, higher values were measured in the F2–4 stages. Free sulfhydryl group concentration, the marker of redox homeostasis, was lower in significant fibrosis (F0–F1: 0.36 ± 0.06 vs. F2–4: 0.29 ± 0.08 mmol/L, p < 0.05). Higher chemiluminescence values, as free radical–antioxidant parameters, were detected in advanced fibrosis stages in erythrocytes (F0–F1: 36.00 ± 37.13 vs. F2–4: 51.47 ± 44.34 RLU%). These data suggest that oxidative stress markers can predict significant fibrosis, with the aim of reducing the number of protocol liver biopsies in patients unlikely to have significant disease; however, their role in distinguishing between the certain fibrosis groups needs further studies.
- Published
- 2024
- Full Text
- View/download PDF
46. Liver Stiffness Evaluation in Chronic Hepatitis C Patients with Cirrhosis before and after Direct-Acting Antivirals
- Author
-
Cristina Stasi and Stefano Brillanti
- Subjects
hepatitis C virus ,chronic hepatitis C ,liver cirrhosis ,liver stiffness ,non-invasive evaluation ,transient elastography ,Biology (General) ,QH301-705.5 - Abstract
After the introduction of direct-acting antivirals, parallel significant clinical progress has been achieved in the assessment of liver fibrosis progression/regression before treatment and during the follow-up of the cirrhotic patients with chronic hepatitis C virus (HCV) infection. The evolution of chronic hepatitis C into liver cirrhosis is correlated with an extensive accumulation of the extracellular matrix, leading to the formation of large amounts of fibrotic tissues that, initially, are concentrated in periportal areas and, in the later stages, surround the nodules of regenerating hepatocytes. The progressive increase in the fibrotic matrix contributes to vascular disturbances (favoring the development of portal hypertension) and to microenvironmental changes. The four clinical stages of liver cirrhosis are predictors for different clinical scenarios. The wide-ranging functions of the liver require different methods for their assessment. The non-invasive evaluation using transient elastography is useful in determining the longitudinal modifications of fibrosis during and after treatment with direct-acting antivirals. The liver stiffness evaluation, known to have a wide range of values in cirrhotic patients, can offer different prognostic implications after sustained virological response. This review discusses the different time points of liver stiffness evaluation that appear to show a more well-defined propensity to identify adequate monitoring schedules for these patients.
- Published
- 2024
- Full Text
- View/download PDF
47. Quantitative ultrasound techniques and biochemical markers to assess liver steatosis and fibrosis in newly diagnosed acromegaly
- Author
-
Coskun, M., Sendur, H. N., Babayeva, A., Cerit, M. N., Cerit, E. T., Yalcin, M. M., Altinova, A. E., Akturk, M., Karakoc, M. A., and Toruner, F. B.
- Published
- 2024
- Full Text
- View/download PDF
48. Shear Wave Elastography for Assessing Liver Stiffness in HCV-Infected Kidney Transplant Recipients after Direct-Acting Antiviral Treatment: A Comparative Study with Magnetic Resonance Elastography.
- Author
-
Almutawakel, Salma, Halleck, Fabian, Dürr, Michael, Grittner, Ulrike, Schrezenmeier, Eva, Budde, Klemens, Althoff, Christian E., Hamm, Bernd, Sack, Ingolf, Fischer, Thomas, and Marticorena Garcia, Stephan R.
- Subjects
- *
SHEAR waves , *MAGNETIC resonance , *KIDNEY transplantation , *ELASTOGRAPHY , *HEPATITIS C virus - Abstract
Hepatitis C virus (HCV) infection can lead to hepatic fibrosis. The advent of direct-acting antivirals (DAAs) has substantially improved sustained virological response (SVR) rates. In this context, kidney transplant recipients (KTRs) are of particular interest due to their higher HCV infection rates and uncertain renal excretion and bioavailability of DAAs. We investigated liver stiffness after DAA treatment in 15 HCV-infected KTRs using ultrasound shear wave elastography (SWE) in comparison with magnetic resonance elastography (MRE). KTRs were treated with DAAs (daclatasvir and sofosbuvir) for three months and underwent SWE at baseline, end of therapy (EOT), and 3 (EOT+3) and 12 months (EOT+12) after EOT. Fourteen patients achieved SVR12. Shear wave speed (SWS)—as a surrogate parameter for tissue stiffness—was substantially lower at all three post-therapeutic timepoints compared with baseline (EOT: −0.42 m/s, p < 0.01; CI = −0.75–−0.09, EOT+3: −0.43 m/s, p < 0.01; CI = −0.75–−0.11, and EOT+12: −0.52 m/s, p < 0.001; CI = −0.84–−0.19), suggesting liver regeneration after viral eradication and end of inflammation. Baseline SWS correlated positively with histopathological fibrosis scores (r = 0.48; CI = −0.11–0.85). Longitudinal results correlated moderately with APRI (r = 0.41; CI = 0.12–0.64) but not with FIB-4 scores (r = 0.12; CI = −0.19–0.41). Although higher on average, SWE-derived measurements correlated strongly with MRE (r = 0.64). In conclusion, SWE is suitable for non-invasive therapy monitoring in KTRs with HCV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. The Relationship Between Right Heart Catheterization Parameters And Albumin Bilirubin (ALBI) Score.
- Author
-
Evlice, Mert
- Subjects
CARDIAC catheterization ,BODY mass index ,CLINICAL trials ,STATISTICAL correlation ,DATA analysis - Abstract
Background: It has been shown that the increase in volume and pressure in the right heart chambers increases liver congestion and liver stiffness. The Albumin-Bilirubin (ALBI) score is a useful and easy-to-use score for objectively assessing liver function. There is no information in the literature regarding the changes in ALBI scores in patients undergoing right heart catheterization(RHC). Objectives: The aim of our study is to investigate the changes in ALBI score and its clinical impact in patients undergoing RHC. Methods: Of the 156 analyzed patients, 20 were excluded. Correlation and regression analysis between ALBI and RHC data was performed on the remaining 136 patients who underwent RHC. The ALBI score was calculated based on serum albumin and total bilirubin levels using the following formula: ALBI= (log10 bilirubin [umol/L] * 0.66) + (albumin [g/L] * -0.085). Results: Of these 136 patients included in the study, the mean age was 45.8±17.2 years, 85 of them (62.5 %) were women, and their body mass index was 27.2±5.9 kg/m2 (Table 1, Table 2). Linear regression analysis was performed for parameters significantly associated with ALBI in univariate and multivariate analysis. As a result of this analysis, mixed venous oxygen saturation [(r= -0.362 p<0.003), (B= -0.345, p=0.089)], mean pulmonary arterial pressure [(r=0.288, p=0.017), (B=0.192, p=0.167))], mean pulmonary capillary wedge pressure [(r=0.526, p<0.001), (B=0.191, p=0.206)], mean right atrial pressure [(B=0.668, p <0.001), (B=0.530, p=0.001))], and cardiac index [(r= -0.384, p=0.002), (B= - 0.293, p=0.064)] were found to be associated with ALBI. In multivariate linear regression analysis, the ALBI score was independently associated with mean right atrial pressure. A mean right atrial pressure greater than 6 mmHg as measured by RHC was associated with increased ALBI scores (cut-off = - 3.53) with a sensitivity of 69.1% and a specificity of 88% (area under the ROC curve = 0.818, 95% CI 0.726-0.909, p<0.001) (Figure 1). Conclusions: ALBI score was independently associated with mean mean right atrial pressure. The ALBI score could be a simple, evidence-based, objective, and discriminatory method to evaluate liver function and gain insight into right atrial pressure in patients with cardiac problems that may affect right heart hemodynamics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
50. Relationships between education and non-alcoholic fatty liver disease.
- Author
-
Koutny, Florian, Aigner, Elmar, Datz, Christian, Gensluckner, Sophie, Maieron, Andreas, Mega, Andrea, Iglseder, Bernhard, Langthaler, Patrick, Frey, Vanessa, Paulweber, Bernhard, Trinka, Eugen, and Wernly, Bernhard
- Subjects
- *
NON-alcoholic fatty liver disease , *HEPATIC fibrosis , *LIVER analysis - Abstract
• NAFLD prevalence in the low education group is 40%, almost twice as high as the high education group (23%, p <0.01). • Individuals with high ISCED had a 46% lower risk of liver steatosis compared to the low ISCED group. • After adjusting for age and sex, individuals with high ISCED experienced a remarkable 48% lower risk of liver steatosis. • Findings emphasize the impact of educational attainment on NAFLD risk and the need for targeted interventions in vulnerable populations. Individuals with lower levels of education are at a higher risk of developing various health conditions due to limited access to healthcare and unhealthy lifestyle choices. However, the association between non-alcoholic fatty liver disease (NAFLD) and educational level remains unclear. Therefore, the aim of this study was to investigate whether there is an independent relationship between NAFLD and educational level as a surrogate marker for socioeconomic status (SES). This cross-sectional study included 8,727 participants from the Paracelsus 10,000 study. The association between NAFLD and educational level was assessed using multivariable logistic regression models and multivariable linear regression. The primary endpoints were NAFLD (FLI score > 60) and liver fibrosis (FIB-4 score > 1.29). Further subgroup analysis with liver stiffness measurement was done. In the study, NAFLD prevalence was 23% among participants with high education, 33% among intermediate, and 40% among those with low education (p <0.01). Importantly, a significantly reduced risk of NAFLD was observed in individuals with higher education, as indicated by an adjusted relative risk of 0.52 (p < 0.01). Furthermore, higher education level was associated with significantly lower odds of NAFLD and fibrosis. Additionally, a subgroup analysis revealed that higher liver stiffness measurements were independently associated with lower levels of education. The study's findings indicate that a lower education level increases the risk of NAFLD independent of confounding factors. Therefore, these findings highlight the potential impact of educational attainment on NAFLD risk and emphasize the need for targeted interventions in vulnerable populations. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.